References
Efficacy figures shown on this site describe outcomes of the tirzepatide molecule in clinical trials, not StaveMD patient results. Individual results vary.
SURMOUNT-1 (ClinicalTrials.gov)
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1). ClinicalTrials.gov Identifier NCT04184622.
Supports: ≈20.9% mean body-weight reduction and up to ~52 lbs average lost at the 15 mg dose over 72 weeks; tirzepatide as a dual GIP + GLP-1 receptor agonist.
https://clinicaltrials.gov/study/NCT04184622 (accessed 2026-07-06)
SURMOUNT-1 (NEJM)
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216.
Supports: Peer-reviewed publication of the SURMOUNT-1 results underlying the 20.9% / 52 lbs / 72-week efficacy figures.
https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 (accessed 2026-07-06)
STEP-1 extension (Diabetes Obes Metab)
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.
Supports: Participants regained roughly two-thirds of their lost weight within one year of stopping semaglutide (/after page).
https://pubmed.ncbi.nlm.nih.gov/35441470/ (accessed 2026-09-01)
GLP-1 cessation meta-regression (eClinicalMedicine 2026)
Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine (The Lancet Discovery Science). 2026.
Supports: Across studies, about 60% of weight lost on treatment is regained one year after cessation (/after page).
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00043-X/fulltext (accessed 2026-09-01)